MarginProbe® System Over 3 Times More Effective in Identifying “Cancer on the Margin” During Lumpectomy than Traditional Intraoperative Methods

By DAY Vision | January 2, 2013

[vc_row][vc_column][vc_column_text]Boston, Mass., January 2, 2013, /PRNewswire/ — Dilon Devices, Inc., announced today that its breakthrough intra-operative tissue assessment tool for early-stage breast cancer surgery, the MarginProbe System, has received Premarket Approval (PMA) by the United States Food and Drug Administration. The technology significantly improves surgeons’ ability to intra-operatively identify “cancer on the margin” and significantly…

Read More